The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain

Neurosci Lett. 2012 Feb 6;508(2):119-22. doi: 10.1016/j.neulet.2011.12.039. Epub 2011 Dec 31.

Abstract

O-1602 is an atypical cannabinoid that acts as an agonist at GPR55, a g protein-coupled receptor that previous studies have indicated may have a pronociceptive role in neuropathic pain. We administered O-1602 to both naive rats and rats that had undergone chronic constriction injury surgery. O-1602 did not cause any changes in hind paw responses to Von Frey hair testing in naive rats. However, O-1602 reversed the desensitising effects of ETOH, which was used as an active and opposing vehicle. Our results are consistent with the hypothesis that GPR55 has a pronociceptive role in neuropathic pain.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cannabidiol / analogs & derivatives
  • Cannabinoids / toxicity*
  • Constriction
  • Cyclohexanes / toxicity*
  • Hindlimb
  • Hyperalgesia / etiology
  • Male
  • Models, Animal
  • Neuralgia / etiology*
  • Rats
  • Rats, Wistar
  • Resorcinols / toxicity*

Substances

  • Cannabinoids
  • Cyclohexanes
  • Resorcinols
  • Cannabidiol
  • O-1602 compound